Navigation Links
OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO

Phase I/II study of OGX-011 and a gemcitabine (GEM)/platinum regimen as first-line therapy in 85 patients with advanced non-small cell lung cancer" Abstract Number: 7596 Session: Lung Cancer, Poster Board # P10 Location: S Hall A2 Session Time: 8:00 a.m. - 12:00 p.m. Presenter: Janessa J. Laskin, M.D. About OGX-011

OGX-011 is designed to specifically inhibit the production of the cell-survival protein, clusterin. Clusterin production is associated with treatment resistance in many cancers and in response to various cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Preclinical studies have shown that inhibition of clusterin can disable the tumor cell's adaptive defences, render the tumor cells susceptible to attack with a variety of cancer therapies, including chemotherapy, and facilitate tumor cell death. OncoGenex and Isis are collaborating on development of OGX-011.

About OncoGenex

OncoGenex is committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex currently has three product candidates in development: OGX-011, OGX-427 and OGX-225. These product candidates are designed to selectively inhibit the production of proteins that are associated with treatment resistance and that are over-produced in response to a variety of cancer treatments. OncoGenex' aim in targeting these particular proteins is to disable the tumor cells' adaptive defenses, render the tumor cells susceptible to attack with a variety of cancer therapies including chemotherapy, and facilitate tumor cell death. More information on OncoGenex and the company's pipeline is available at www.oncogenex.com.


'"/>




Page: 1 2 3 4

Related medicine technology :

1. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OncoGenex and Isis Announce OGX Data Presented ASCO
(Date:7/28/2014)... Calif. , July 28, 2014 ... leader in lifestyle healthcare and subsidiary ... that it has acquired Physician Recommended Nutriceuticals (PRN) ... omega-3s, and related products for dry ... Plymouth Meeting, PA, in a transaction worth up ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
Breaking Medicine Technology:ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... Delaware, October 10, 2011 As the ... gigabytes of health and health-related technology information, and the ... providers are going to adopt new patterns to successfully ... reimbursement processes. In order to cope with ...
... Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) ... strategic collaboration for the development, commercialization and supply of ... AKP,s formulation of human parathyroid hormone (human PTH 1-34), ... risk of fracture.  Under the terms ...
Cached Medicine Technology:MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 2MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 3MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 4Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 2Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 3Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 4
(Date:7/29/2014)... Gout was one called “the disease of kings”. However, ... statement essentially moot since many people of today can dine ... are the resources to deal with such a devious disease ... for it, but the effects of the disease are devastating ... , Alternative medicine specialist and author Joe Barton ...
(Date:7/29/2014)... 2014 Consilium Staffing, Your Partner in Locum ... halfway point of 2014, with strong indications the Irving, Texas-based ... of this year. , “This is a great time to ... Consilium Staffing. , “We are proud of what we ... we are even more excited about how things are shaping ...
(Date:7/29/2014)... Guests at Napa Valley's quintessential luxury resort, Auberge ... experience. The top of each luxurious resort bed is adorned ... expertly crafted, 100% Egyptian cotton white duvets and pillow shams ... closer look, words are woven in the linens that serve ... , Intentional breathing and visualization are keys to relaxing ...
(Date:7/29/2014)... 2014 A Forever Recovery , an ... to a great start and gives them a solid foundation ... of the National Cherry Festival kickoff concert held on July ... was co-sponsored by Miller Lite and in partnership with WKLT ... Bay Side Music Stage presented by Blue Cross Blue Shield ...
(Date:7/29/2014)... 2014 Recently, Stwd.co.uk, a distinguished online supplier ... evening dresses . As a summer special offer, all ... to 70 percent off. All new and old customers can ... are proud to announce the new evening outfits. They want ... “We feel happy to launch the big sale. Our cheap ...
Breaking Medicine News(10 mins):Health News:Gout Natural Remedy Report Review | The Ultimate Secret to Eliminating Gout Naturally – Vinamy.com 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:A Forever Recovery Sponsors National Cherry Festival Kickoff Concert Featuring Collective Soul on July 5 in Traverse City, MI 2Health News:Cheap Prom Dresses Available At Popular Online Store Stwd.co.uk 2
... June 17 The business of recruiting,university students ... technology industries that rely on this talent pool ... skills. Yet many,companies haven,t changed their university recruiting ... Best Practices, LLC - a leading,pharmaceutical research firm., ...
... linked to disease found in Sub-Saharan Africans , , , TUESDAY, ... a herpes virus and an atypical form of type 2 diabetes ... , Researchers in France, writing in the June 18 issue ... , noted a possible tie between the presence of antibodies for ...
... researcher at the Center for Molecular and Behavioral ... the recent recipient of a "2008 Young Investigator ... to Mental Health Research (previously known as the ... NARSAD is the world,s leading donor-supported organization dedicated ...
... (AMA) announced today the re-election of William A. Hazel, ... consecutive term,on the AMA Board of Trustees., "I ... help physicians achieve,our shared goal of providing the best ... Hazel has been a participant in the AMA House ...
... proper use and possible long-term effects of hydroxyurea in ... influencing doctors to avoid prescribing it to those in ... by specialists at Johns Hopkins. , "We know that ... this drug, which is the only one we have ...
... Pennsylvania School of Medicine found that the activation of ... biology leads to an increase in lung stem cells. ... repair after injury or disease. The investigators published their ... in Nature Genetics . , "The current findings ...
Cached Medicine News:Health News:Best Practices: Achieving Excellence in Staffing and Recruiting Methods 2Health News:Study Ties Herpes Virus to Emerging Form of Diabetes 2Health News:Rutgers scientist receives prestigious 'Young Investigator Award' 2Health News:Effective treatment for sickle cell underused by doctors 2Health News:Penn researchers find key developmental pathway activates lung stem cells 2
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... full-featured healthcare bed system providing a comfortable, ... management of larger patients, ,INDICATIONS: ,Large ... patients at risk for pressure ulcers, ... lbs. (including accessories), ,PRECAUTION: ,Side Rails ...
... beds feature folding head end and foot end deck ... head end and foot end deck panels folded the ... 67". This compact length makes storage, delivery and pick ... is not available on Model 4748B, Basic Maxi Rest ...
Medicine Products: